A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections
Copyright © 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved..
As the world continues to confront severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus (RSV) is also causing severe respiratory illness in millions of infants, elderly individuals, and immunocompromised people globally. Exacerbating the situation is the fact that co-infection with multiple viruses is occurring, something which has greatly increased the clinical severity of the infections. Thus, our team developed a bivalent vaccine that delivered mRNAs encoding SARS-CoV-2 Omicron spike (S) and RSV fusion (F) proteins simultaneously, SF-LNP, which induced S and F protein-specific binding antibodies and cellular immune responses in BALB/c mice. Moreover, SF-LNP immunization effectively protected BALB/c mice from RSV infection and hamsters from SARS-CoV-2 Omicron infection. Notably, our study pointed out the antigenic competition problem of bivalent vaccines and provided a solution. Overall, our results demonstrated the potential of preventing two infectious diseases with a single vaccine and provided a paradigm for the subsequent design of multivalent vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Molecular therapy : the journal of the American Society of Gene Therapy - 32(2024), 4 vom: 03. Apr., Seite 1033-1047 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Namei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ymthe.2024.02.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368311236 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368311236 | ||
| 003 | DE-627 | ||
| 005 | 20240408232341.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240211s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ymthe.2024.02.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM368311236 | ||
| 035 | |a (NLM)38341613 | ||
| 035 | |a (PII)S1525-0016(24)00080-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Namei |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a As the world continues to confront severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus (RSV) is also causing severe respiratory illness in millions of infants, elderly individuals, and immunocompromised people globally. Exacerbating the situation is the fact that co-infection with multiple viruses is occurring, something which has greatly increased the clinical severity of the infections. Thus, our team developed a bivalent vaccine that delivered mRNAs encoding SARS-CoV-2 Omicron spike (S) and RSV fusion (F) proteins simultaneously, SF-LNP, which induced S and F protein-specific binding antibodies and cellular immune responses in BALB/c mice. Moreover, SF-LNP immunization effectively protected BALB/c mice from RSV infection and hamsters from SARS-CoV-2 Omicron infection. Notably, our study pointed out the antigenic competition problem of bivalent vaccines and provided a solution. Overall, our results demonstrated the potential of preventing two infectious diseases with a single vaccine and provided a paradigm for the subsequent design of multivalent vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antigen competition | |
| 650 | 4 | |a bivalent vaccine | |
| 650 | 4 | |a lipid nanoparticle | |
| 650 | 4 | |a mRNA | |
| 650 | 4 | |a respiratory infectious disease | |
| 650 | 4 | |a respiratory syncytial virus | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Combined |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Respiratory Syncytial Virus Vaccines |2 NLM | |
| 650 | 7 | |a Viral Fusion Proteins |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Zhang, Jiachen |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yanqiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xinghai |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jinge |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Entao |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Xiaoming |e verfasserin |4 aut | |
| 700 | 1 | |a Chuai, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Chiu, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yucai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy : the journal of the American Society of Gene Therapy |d 2000 |g 32(2024), 4 vom: 03. Apr., Seite 1033-1047 |w (DE-627)NLM108239381 |x 1525-0024 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:4 |g day:03 |g month:04 |g pages:1033-1047 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ymthe.2024.02.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 4 |b 03 |c 04 |h 1033-1047 | ||